

**Sirolimus Gel “Xian Luo Li”
Launched in China**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Managing Director & CEO: Jin Shiomura) launched, on January 1, 2024 in China, sirolimus gel “Xian Luo Li” (named RAPALIMUS® gel 0.2% in Japan), which was covered by medical insurance on the same day after listed in NRDL on December 13, 2023 for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) for patients 6 years and older.

In China, approximately 63,000 people have TSC, and estimated 45,000 have TSC-related facial angiofibroma.

This drug is the world’s first topical agent approved in Japan for tuberous sclerosis-associated skin lesions and launched in June 2018 under the name of “RAPALIMUS® gel 0.2%” after receiving Sakigake “fast-track” designation and orphan drug status.

“Xian Luo Li”, launched overseas following “HYFTOR” in US and Europe, is prescribed to patients through the activities to provide drug information by our affiliated company in China, Jiangsu Nobelpharma Co., Ltd. (Taizhou, Jiangsu; General Manager: Rongzhe Jiang).

We are genuinely glad this launch has enabled us to contribute to the treatment of angiofibroma associated with TSC in China.

We are determined to continue contributing to society by providing critical but neglected pharmaceuticals and medical devices.

[Contact for inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

phone: 03-6670-3800